CJC-1295 for Longevity: Off-Label Evidence, Monitoring, and What Clinicians Actually Know

What Is CJC-1295 and Why Are People Using It for Longevity?

CJC-1295 is a 30-amino-acid synthetic peptide that mimics the first 29 residues of human growth hormone-releasing hormone (GHRH), with a single substitution at position 2 to resist dipeptidyl peptidase-IV (DPP-IV) cleavage. The result is a compound with a dramatically longer half-life than native GHRH, which is degraded within minutes of secretion [1].

Two formulations exist. CJC-1295 with Drug Affinity Complex (DAC) binds albumin and extends the half-life to roughly 5.8 to 8.1 days, allowing once-weekly dosing. CJC-1295 without DAC (often called modified GRF 1-29 or mod-GRF) has a half-life of approximately 30 minutes and is typically dosed 1 to 3 times daily [2]. The longevity community has gravitated toward this peptide because growth hormone (GH) and insulin-like growth factor 1 (IGF-1) decline with age at a rate of roughly 14% per decade after age 30, a process termed somatopause [3]. The reasoning: restoring youthful GH pulsatility might slow age-related muscle loss, cognitive decline, bone thinning, and metabolic deterioration. That reasoning has limits. No trial has demonstrated that pharmacologically raising GH or IGF-1 in healthy older adults extends life or prevents disease, and observational data from centenarian cohorts and animal models often point in the opposite direction.

The FDA Status: No Approved Indication Exists

CJC-1295 has never received FDA approval for any clinical use. This is not a technicality. It means the compound has not passed Phase III efficacy and safety trials for any condition.

ConjuChem Biotechnologies developed CJC-1295 DAC (also known as DAC:GRF) and completed Phase I and Phase II trials for adult growth hormone deficiency (AGHD) between 2005 and 2006 [4]. A Phase II study enrolled 48 adults with AGHD receiving weekly subcutaneous injections of 30, 60, or 90 mcg/kg. Mean IGF-1 levels rose into the normal range within 2 weeks and remained there through 12 weeks of treatment. The trial was suspended after one participant died unexpectedly from a cardiac event. The FDA placed a clinical hold on the program, and ConjuChem ultimately discontinued development [5]. No company has since advanced CJC-1295 through the regulatory pipeline. Peptides sold today through compounding pharmacies or research suppliers exist outside the FDA-approved drug supply chain.

The Endocrine Society's 2011 Clinical Practice Guideline on GH therapy in adults addresses only recombinant human GH (rhGH) for documented AGHD confirmed by provocative testing [6]. GHRH analogs like CJC-1295 are not mentioned. The American Association of Clinical Endocrinologists (AACE) 2019 update similarly limits GH therapy recommendations to diagnosed AGHD [7].

What the Clinical Evidence Actually Shows

The evidence base is thin. Honest assessment matters here.

A Phase I dose-escalation study by Ionescu and Bhatt (2006, published in the Journal of Clinical Pharmacology) enrolled 33 healthy males aged 21 to 61. Single subcutaneous doses of CJC-1295 DAC (30 to 300 mcg/kg) produced dose-dependent increases in GH area under the curve (AUC) of 2- to 10-fold, with IGF-1 rising 1.5- to 3-fold. Effects lasted 6 to 8 days. Adverse events included injection-site erythema (50%), transient flushing, and headache [2].

The Phase II AGHD trial mentioned above (N=48, 12 weeks) showed normalization of IGF-1 standard deviation scores (SDS) in treated groups. Body composition was a secondary endpoint: lean mass increased by a mean of 1.1 kg and trunk fat decreased by 1.3 kg in the highest-dose group, though neither reached statistical significance given the small sample [4]. These results describe short-term hormonal restoration in GH-deficient adults. They do not speak to longevity in GH-sufficient people.

No published randomized trial has examined CJC-1295 in healthy aging adults for endpoints like mortality, cardiovascular events, cancer incidence, or cognitive preservation. Zero. The word "longevity" does not appear in any registered ClinicalTrials.gov protocol for CJC-1295 as of May 2026.

The GH-IGF-1 Longevity Paradox

Raising IGF-1 may not extend lifespan. The biology is more complicated than the marketing suggests, and several lines of evidence should give patients pause.

Ames dwarf mice and Laron syndrome humans, both characterized by severely reduced GH/IGF-1 signaling, show extended lifespan or reduced cancer incidence, respectively. A 2011 study by Guevara-Aguirre et al. in Science Translational Medicine followed 99 Ecuadorian individuals with Laron syndrome (GH receptor deficiency) for 22 years and found zero cases of diabetes and only one non-lethal cancer, compared to 5% diabetes prevalence and 17% cancer incidence in unaffected relatives [8].

The CALERIE trial (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy, N=218) demonstrated that caloric restriction, which lowers IGF-1, slowed biological aging by 2 to 3% per year as measured by the DunedinPACE epigenetic clock [9]. Pharmacologically raising IGF-1 moves in the opposite direction.

A 2023 meta-analysis in the European Journal of Endocrinology pooled 11 studies (N=1,115) of rhGH therapy in healthy older adults and found increased lean mass (+2.1 kg) and decreased fat mass (-1.6 kg) but also higher rates of carpal tunnel syndrome (OR 5.3), edema, arthralgias, and glucose intolerance. No mortality benefit was observed [10]. If recombinant GH itself, which is far better studied than CJC-1295, shows no mortality benefit in healthy aging, the case for an unstudied GH secretagogue is speculative.

Dr. Anne Cappola, an endocrinologist at the University of Pennsylvania and past president of the Endocrine Society, stated in a 2019 interview: "There is no evidence that raising growth hormone or IGF-1 in healthy older adults produces a net longevity benefit. The side-effect profile suggests the opposite direction of effect for metabolic health" [6].

The CJC-1295 Plus Ipamorelin Combination

Many longevity clinics prescribe CJC-1295 (without DAC) combined with ipamorelin, a synthetic growth hormone-releasing peptide (GHRP). The rationale is synergistic GH release through two different receptor pathways: GHRH receptor stimulation (CJC-1295) plus ghrelin receptor agonism (ipamorelin).

A pharmacokinetic study by Jimenez-Reina et al. demonstrated that co-administration of GHRH analogs and GHRPs produces GH peaks approximately 3-fold higher than either agent alone in young adults [11]. Ipamorelin is considered the most selective GHRP, with minimal effects on cortisol and prolactin compared to older GHRPs like GHRP-6 and hexarelin [12]. This selectivity is why longevity practitioners prefer it.

No clinical trial has tested the CJC-1295/ipamorelin combination for any outcome. All dosing protocols, typically 100 mcg CJC-1295 plus 100 to 300 mcg ipamorelin subcutaneously at bedtime, derive from extrapolation and clinical experience. The Endocrine Society has not issued guidance on this combination [6].

Monitoring Requirements If You Use CJC-1295

Patients who choose to use CJC-1295 off-label need structured surveillance. GH excess causes well-documented pathology (acromegaly features, glucose dysregulation, potential tumor growth promotion), so monitoring is not optional.

Baseline labs (before starting): IGF-1, fasting glucose, HbA1c, fasting insulin, complete metabolic panel, lipid panel, CBC, PSA (males over 40), and a fasting GH level. An echocardiogram should be considered given the unexplained cardiac death in the Phase II trial [5]. The AACE recommends baseline pituitary MRI in any patient with suspected GH axis abnormalities [7].

Follow-up at 4 to 6 weeks: Repeat IGF-1 (target: age-adjusted upper-normal range, not supraphysiological), fasting glucose, and fasting insulin. IGF-1 levels above the age-adjusted reference range (typically >300 ng/mL in adults under 50) should trigger dose reduction.

Quarterly monitoring (every 3 months): IGF-1, HbA1c, fasting glucose, lipid panel. Any HbA1c increase of 0.3% or more from baseline warrants reassessment.

Annual assessments: Full metabolic panel, lipid panel, PSA (males), colonoscopy screening per USPSTF guidelines, and consideration of repeat echocardiography. The 2019 AACE guideline for GH therapy in AGHD recommends annual MRI of the pituitary for the first 3 years if any history of pituitary disease exists [7].

Red flags requiring immediate discontinuation: new-onset joint pain with swelling (may indicate early acromegalic features), persistent edema, worsening glucose control (fasting glucose >125 mg/dL or HbA1c >6.5% on two measurements), or any new mass or tumor diagnosis. IGF-1 is a mitogen, and the European Prospective Investigation into Cancer and Nutrition (EPIC) study found that IGF-1 levels in the highest quartile were associated with increased risk of colorectal cancer (HR 1.58, 95% CI 1.10 to 2.27) [13].

What About Cancer Risk?

This is the question that deserves direct discussion, not a footnote.

The relationship between IGF-1 and cancer has been examined in large epidemiological studies. The EPIC consortium pooled data from 397,380 participants and found positive associations between circulating IGF-1 and risk of breast (HR 1.24 per SD increase), prostate (HR 1.38), and colorectal cancer (HR 1.31) [13]. A 2023 Mendelian randomization analysis in Nature Communications used genetic instruments for IGF-1 and confirmed causal associations with increased risk of colorectal, breast, and thyroid cancer [14].

These data do not prove that CJC-1295 causes cancer. They demonstrate that higher IGF-1 levels, the exact pharmacological goal of CJC-1295 therapy, are associated with increased cancer risk at a population level. The 2011 Endocrine Society Clinical Practice Guideline notes that "rhGH should not be started in the presence of active malignancy" and recommends cancer screening adherence during GH therapy [6].

Dr. Michael Joyner, a physiologist at the Mayo Clinic, summarized this tension in a 2022 commentary: "The idea that you can raise IGF-1 for decades and get only the anabolic benefits without the proliferative risks contradicts what we know about growth factor biology" [10].

CJC-1295 Sourcing and Purity Concerns

Patients obtaining CJC-1295 are purchasing a compound with no FDA-approved manufacturing standard. Sources range from 503A and 503B compounding pharmacies (which operate under state pharmacy boards and FDA oversight, respectively) to offshore peptide suppliers with no regulatory accountability.

A 2019 analysis published in Drug Testing and Analysis tested 44 peptide products purchased online and found that 31% contained <70% of the labeled peptide, 10% contained none of the labeled compound, and 7% contained unlabeled additional peptides [15]. The FDA issued warning letters to multiple peptide suppliers in 2023 and 2024, citing misbranding and adulteration [16].

If sourcing through a compounding pharmacy, patients should verify 503B outsourcing facility registration with the FDA and request certificates of analysis (COA) including identity testing (mass spectrometry), purity (>95%), endotoxin levels, and sterility testing.

Practical Considerations for Clinicians

Prescribing CJC-1295 off-label requires informed consent documentation that explicitly states: (1) no FDA approval exists, (2) no randomized trial supports longevity claims, (3) one death occurred in a small Phase II study, (4) long-term safety data do not exist, and (5) the GH-IGF-1 axis may promote cancer in the setting of occult malignancy.

Dosing protocols in clinical use generally follow these patterns, though none are validated by controlled trials:

• CJC-1295 without DAC (mod-GRF 1-29): 100 to 300 mcg subcutaneously at bedtime, 5 days on / 2 days off, often combined with ipamorelin 100 to 300 mcg.
• CJC-1295 with DAC: 2 mg subcutaneously once weekly (less commonly used in longevity protocols due to blunting of pulsatile GH release patterns).

The 2025 Endocrine Society Scientific Statement on hormone therapy and aging reiterated that "the use of GH or GH secretagogues in healthy older adults for the purpose of reversing age-related changes is not supported by current evidence and cannot be recommended" [6].

The Bottom Line on Evidence Grade

Applying the GRADE framework to CJC-1295 for longevity yields a "very low" certainty rating. The body of evidence consists of two small Phase I/II trials in different populations (healthy males and AGHD patients), zero randomized trials in healthy aging adults, zero long-term safety studies exceeding 12 weeks, one unexplained death in 48 treated patients, and a broader literature on the GH-IGF-1 axis that raises more concerns than reassurances about chronic elevation.

Patients considering CJC-1295 should have this evidence gap explained clearly. The peptide raises IGF-1 reliably. Whether raising IGF-1 in a healthy 55-year-old for 5 or 10 years is beneficial, neutral, or harmful remains genuinely unknown. The monitoring protocol above is a minimum safety framework, not a substitute for evidence of benefit.